Evidence map›Paper›PMID 20188257›Full record

ArticleVaccine2010

Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Shixia Wang, Innocent Mboudjeka, Jon D Goguen, Shan Lu

Abstract read
In one paragraph

Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. DNA immunization.Current protocols in microbiology · 2013
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shixia WangLaboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605-2397, United States.
Innocent Mboudjeka
Jon D Goguen
Shan Lu
University of Massachusetts Chan Medical School · US

Funding

Multi-gene Subunit Vaccine Platform Against Y. pestisU01AI078073 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2008 to 2011
$1.7M
NIAID NIH HHS 1U01AI078073NIAID NIH HHS U01 AI078073
6 · The paper itself

Abstract

The use of a DNA immunization approach to deliver protective antigens against Yersinia pestis (Y. pestis) has been successful in previously reported studies. In the current study, the gene designs for V and F1, two well-studied virulent factors serving as main targets for vaccine development, were altered to explore additional options in hopes of improving the protective immunity of DNA vaccines expressing these two antigens. Compared to the wild type V gene DNA vaccines, the use of codon optimized V gene sequences was effective in improving the antigen expression, titers of anti-V antibody responses, and survival against a mucosal lethal challenge. For the F1 DNA vaccine, removal of the N-terminal hydrophobic region was able to improve protective immunity. However, adding a mammalian signal peptide sequence to F1 actually led to reduced protection despite it inducing slightly higher anti-F1 antibody responses. The F1 gene can be fused with a gene coding for YscF, a newly confirmed partial protective antigen for Y. pestis, to produce DNA vaccines that express fused F1 and YscF antigens. One design, in particular, that had YscF fused to the downstream sequence of F1, produced better protection than separate F1 or YscF DNA vaccines, suggesting a potential synergistic effect between these two antigens. Findings from the above studies indicated that there are multiple approaches to optimize the protective immunity for plague DNA vaccines. Most importantly, proper antigen engineering to produce optimal antigen gene inserts in DNA vaccines can clearly play a major role in the future designs of a wide range of DNA vaccines.

Indexed as

Protein EngineeringAnimalsAntibodies, BacterialAntigens, BacterialCell LineFemaleImmunoglobulin GMiceMice, Inbred BALB CPlaguePlague VaccineRecombinant Fusion ProteinsVaccines, DNAVirulence FactorsYersinia pestisAntibodies, BacterialAntigens, BacterialImmunoglobulin GPlague VaccineRecombinant Fusion ProteinsVaccines, DNAVirulence Factors

Identifiers

PMID20188257
PMCPMC2830910
OpenAlexW2064948013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.